| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
ADHD is characterized mainly by dysfunction in inhibition and attention. Methylphenidate (MPH) and Atomoxetine (ATX) have been recommended as a primary medication. We examined the pharmacological effects of MPH and ATX in ADHD children using fNIRS in a randomized, double-blind, placebo-controlled, crossover design during an inhibition and attention task. Firstly, our fNIRS-based measurements visualized both medications modulated hemodynamic responses in the right prefrontal cortex (rPFC) during an inhibition task while pre-medication and a placebo did not in ADHD. Secondly, we visualized MPH modulated hemodynamic responses in rPFC and ATX in rPFC and the right inferior parietal lobe (rIPL) during an attention task while pre-medication and a placebo did not in ADHD. Consequently, our studies reveal that the activation pattern in rIPL could serve as an objective neurobiological marker to differentiate the neuropharmacological effects of ATX and MPH on ADHD regarding attentional control.
|
